PE/Dazzle™ 594 anti-human IL-6 Antibody

Product Details

Verified Reactivity

Human

Antibody Type

Monoclonal

Host Species

Rat

Immunogen

COS-7- expressed, recombinant human IL-6

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)

Preparation

The antibody was purified by affinity chromatography and conjugated with PE/Dazzle™ 594 under optimal conditions.

Concentration

Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Application

ICFC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

* PE/Dazzle™ 594 has a maximum excitation of 566 nm and a maximum emission of 610 nm.

Excitation Laser

Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)

Application Notes

ELISA or ELISPOT Capture^1-3,7: The purified MQ2-13A5 antibody is useful as the capture antibody in a sandwich ELISA or ELISPOT assay, when used in conjunction with the biotinylated MQ2-39C3 antibody (Cat. No. 501202) as the detecting antibody.

Neutralization^1-3,5,6: The Ultra-LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of human IL-6 bioactivity (Cat. No. 501110). The MQ2-13A5 antibody can neutralize the bioactivity of natural or recombinant IL-6.

Additional applications (for the relevant formats) include: intracellular flow cytometry¹⁰.

Application References

(PubMed link indicates BioLegend citation)

1. Abrams J, et al. 1992. Immunol. Rev. 127:5.
2. Abrams JS. 2001. Curr. Protoc. Immunol. Unit 6.20.
3. Gaines Das R, et al. 1993. J. Immunol. Methods 160:147.
4. Enriquez J, et al. 2002. Adv. Perit Dial. 18:177.
5. Zou JP, et al. 1999. J. Immunol. 162:4882.
6. Wyant TL, et al. 1999. Infect. Immun. 67:1338.
7. Lesmeister MJ, et al. 2005. Reprod. Biol. Endocrinol. 3:74.
8. Terasaka Y, et al. 2010. Invest. Ophthalmol. Vis. Sci. 51:2441 PubMed
9. Girndt M, et al. 1998. J. Am. Soc. Nephrol. 9:1689.

Product Citations

1. Lee HS, et al. 2023. Biol Pharm Bull. 46:542. PubMed
2. Billing F, et al. 2021. ACS Appl Mater Interfaces. 13:55534. PubMed
3. Kreutmair S, et al. 2021. Immunity. . PubMed

RRID

AB_2810621 (BioLegend Cat. No. 501121)
AB_2810621 (BioLegend Cat. No. 501122)

Antigen Details

Structure

Neuropoietic cytokine family; 26 kD (Mammalian)

Bioactivity

Hematopoiesis; antigen-specific immune responses, inflammatory reactions; acute phase reaction

Cell Sources

T cells, B cells, macrophages, bone marrow stromal cells, fibroblasts, keratinocytes, mesangium, astrocytes, endothelial cells

Cell Targets

T cells, B cells, hepatocytes, cholinergic neurons

Receptors

Heterodimer IL-6Rα (CD126)/IL-6Rβ (CD130; gp130)

Biology Area

Cell Biology, Immunology, Innate Immunity, Neuroinflammation, Neuroscience

Molecular Family

Cytokines/Chemokines

Antigen References

1. Fitzgerald, K., et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. Hirano T. 1998. Int. Rev. Immunol. 16:249.
3. Patterson P. 1992. Curr. Opin. Neurobiol. 2:94.
4. van Oers M, et al. 1993. Ann. Hematol. 66:219.

Regulation

Upregulated by IL-1, TNF, PDGF, IFN-β, TNF-α, NGF, and IL-17; downregulated by glucocorticoids IL-4 and TGF-β

Gene ID

3569 View all products for this Gene ID

UniProt

View information about IL-6 on UniProt.org

Related Protocols

• Intracellular Flow Cytometry Staining Protocol

Other Formats